GSK and Impax announce positive topline results of ASCEND-PD Phase III study
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) and Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. (NASDAQ: IPXL) announced top-line results of the ASCEND-PD Phase III clinical study of IPX066 versus carbidopa-levodopa plus entacapone (CLE), in patients with advanced Parkinson's disease (PD).
Pfizer Wins Viagra Patent Trial
- Details
- Category: Pfizer
Pfizer Inc. announced today that it has prevailed in its patent infringement action against Teva Pharmaceuticals USA, Inc. in the United States District Court for the Eastern District of Virginia.
Bayer to support WHO and Stop Tuberculosis Partnership in fighting tuberculosis
- Details
- Category: Bayer
Bayer HealthCare has agreed to support the World Health Organization (WHO) and the Stop TB Partnership in the fight against multidrug-resistant tuberculosis (MDR-TB) by making 620,000 tablets of the antibiotic moxifloxacin available to WHO.
Merck and Serum Institute Announce Collaboration
- Details
- Category: Merck
Merck (NYSE: MRK), known outside the United States and Canada as MSD, and Serum Institute of India Limited, an Indian company, announced an agreement to work together to develop and commercialize a pneumococcal conjugate vaccine (PCV) for use in the emerging and developing world countries.
Results of ROCKET AF Study of Bayer’s Xarelto® (Rivaroxaban)
- Details
- Category: Bayer
Data published in the New England Journal of Medicine demonstrate that Bayer's once-daily, oral, direct Factor Xa inhibitor rivaroxaban (Xarelto®) successfully met the primary efficacy outcome while maintaining comparable overall bleeding rates versus warfarin in the ROCKET AF study.
Lundbeck's first half report 2011
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) reports second quarter revenue of DKK 4,100 million growing 9% compared to the same period last year. In constant exchange rates revenue for the quarter increased 13%.
Lilly Announces Review of Data on Long-Term Raloxifene Treatment
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) announced that data on EVISTA® (raloxifene HCl tablets) therapy for more than three years was published online in Current Medical Research & Opinion. The review includes summaries of previously published information; new, previously unpublished observations; and new data on EVISTA use.
More Pharma News ...
- Many Americans May Have Low Vitamin D Levels
- Roche's investigational treatment for asthma met its primary endpoint
- Bristol-Myers Squibb Delivers Excellent Second Quarter
- NCCN Receives $2M Educational Grant from Pfizer
- Pfizer Reports Second-Quarter 2011 Results
- Sanofi's sales growth of 6.9% thanks to Genzyme acquisition
- Bayer continues positive momentum